Framingham-based Boston Heart Lab has announced its appointment of new CEO Susan Hertzberg and its closing of a $10 million Series C funding round, revealed earlier this month in a regulatory filing. The financing was led by Bain Capital Ventures.
Hertzberg replaces Boston Heart Lab’s founding CEO Wolfgang Daum, who will operate as a consultant to the company. She joins Boston Heart Lab having previously served as president and CEO of Ipsogen Inc., the North American division of French cancer and molecular diagnostics firm Ipsogen SA. She has also held executive appointments at Abbott Diagnostics and management roles at Quest Diagnostics Inc. Hertzberg, who serves on the board of healthcare services firm Theracare, earned an MBA from Columbia University and a bachelor’s degree from Clemson University.